Case Presentation. Pei Lin, M. D.

Size: px
Start display at page:

Download "Case Presentation. Pei Lin, M. D."

Transcription

1 Case Presentation Pei Lin, M. D.

2 History A 26 yr man reports a history of numerous skin and upper respiratory infections as a child, including lymphadenitis and meningitis. In March 2013 during a preoperative evaluation to debride MRSA of the right shoulder, CBC showed WBC 2.2 k/ul and platelet count 120K/uL. In June 5, 2013, seen for gingivitis and sinusitis WBC 1.84 k/ul, Hgb 12.5 g/dl, Platelet count 165.

3 History He was referred to a local hematologist BM biopsy showed hypocellular marrow, moderate myeloid hypoplasia and some dysmegakaryopoesis, no increased blasts. After a possible diagnosis of myelodysplasia was made, the patient did not go for further evaluations due to lack of medical insurance.

4 History & PE Hydroceletomy surgery right testis, 2012 Genital warts Migraine 2006 Meningitis 2015 Arthralgia, back pain and joint swelling Mother: Rheumatoid arthritis, lupus, Sister: Psoriasis, father: None

5 PB (2017) WBC 1.3K/uL ( ) Hgb 11.5gm/dL ( ) Platelet 184K/uL ( ) Neutrophil 52.0% Lymphocyte 44.8% Monocyte 2.4% Eosinophil 0.8% Neutrophil Abs 0.65K/uL L ( ) Lymphocyte Abs 0.56K/uL L ( ) Monocyte Abs 0.03K/uL L ( ) Eosinophil

6 Bone Marrow osteoclast-like megs CD61

7 BMA

8 SSC-A CD123 APC-A HLA-DR CD34 PerCP-Cy5-5-A SSC-A CD123 APC-A HLA-DR FITC-A CD34 PerCP-Cy5-5-A The patient % Blast 01= 1.41% 1.45% % 97.30% 0.98% % % % % CD34 PerCP-Cy5-5-A 0.82% % HLA-DR FITC-A pdc 18.38% % HLADR= CD10 PE-Cy7-A Normal control 10 5 Hematogones 74.23% 24.43% % 10 5 MFI= CD117 PE-A 67.41% % CD34 PerCP-Cy5-5-A % HLA-DR FITC-A 79.97% HLADR= CD MFI= CD117 PE-A

9 SSC-A SSC-A Our Patient 63 year old woman Mono= 4.7% Mono= 0.6% CD64 PE-A CD64 PE-A

10 SSC LAM PE-A The Patient CD19 gate= 1.7% CD KAP FITC-A

11 CD56 PE-A CD57 FITC-A SSC-A CD3 PE-Cy7-A CD3 PE-Cy7-A 54.98% 45.02% 48.34% 51.66% % % CD3= 30.0% % CD4 PerCP-Cy5-5-A 14.74% 3.83% CD8 APC-A CD3 PE-Cy7-A 3.87% 10 5 NK cells CD3 PE-Cy7-A CD8 APC-A

12 Ancillary tests Karyotype: 46,XY FISH: trisomy 8 in 6% of analyzed cells Negative for -7/7q, del5q or 17p

13 The most likely diagnosis is A: Aplastic anemia B: Severe congenital neutropenia C: Primary immune deficiency associated cytopenia D: Myelodysplastic syndrome E: Familial MDS (myeloid neoplasms with germline predisposition)

14 VAF: 49%

15 Diagnosis Myelodysplastic syndrome with multilineage dysplatia associated with GATA2 mutation (GATA2 deficiency)

16 What s next What test should be done next? Skin fibroblasts to test for germline GATA2 mutation Bucal swap to test for germline GATA2 mutation Screen family members for GATA2 mutation, and possible SCT donor Search for matched unrelated SCT donor

17 Skin Punch biopsy p.arg396trp (CGG>TGG): c.1186 C>T in exon 6 of the GATA2 gene Missense mutation

18 Diagnosis Myelodysplastic syndrome with multilineage dysplatia associated with germline GATA2 mutation (GATA2 deficiency) SCT planned for December 2018

19 GATA2 is essential for Hematopoiesis Transcription Factor on 3q21 GATA2 is expressed in hematopoietic and nonhematopoietic embryonic stem cells bind the DNA sequence (A/T)GATA(A/G) through two zinc finger (ZnF) domains Crit Rev Oncol Hematol Apr;82(1):1-17.

20 2011

21 PAP: Pulmonary alveolar proteinosis MonoMAC syndrome

22 GATA2 mutations Null Regulator Missense Credit: NIAID

23 Mechanisms Deletions, missense, nonsense, frameshift, splice site changes Most occur in the 2 zinc fingers, leading to a nonfunctional protein unable to bind DNA or other TF partners. Intronic regulatory elements (intron 5 enhancer lead to reduced transcription of the cis allele)

24 Clinical features of GATA2 deficiency Stroke and Thrombosis Infection HPV EBV MAC Lymphedema, Hearing loss (Emberger syndrome) Pulmonary alveolar proteinosis Autoimmune hepatitis Rheumatologic symptoms: erythema nodosum, panniculitis, or arthralgias Miscarriage/preterm labor Autism Cytopenia (MDS/AML) Modified from Michael A. Spinner et al. Blood 2014;123:

25 Clinical, pathologic, and Imaging of GATA2 deficiency. mycobacteria infection PAP alveolar space with lipoproteinaceous Panniculitis/EN Brain infarct EBV+ spindle cell lesion Michael A. Spinner et al. Blood 2014;123:

26 Associated mutations Myeloid neoplasms (MNs) of any type eventually develop in up to 75% of patients (MDS, AML, CMML, rarely ALL) Average age of onset for MNs is 12 to 35 years old, median: 19.7 year SETBP1, ASXL1, STAG2, RUNX1, CBL, EZH2, NRAS, JAK3, and PTPN11 CMML with ASXL1

27 GATA2 deficiency in Pediatric MDS Associated with -7 (41% ), trisomy 8 (15%), and trisomy 1q. GATA2 deficiency accounts for 7% of primary pediatric MDS and 15% of children with advanced MDS In pediatric patients with MDS and -7, 37% have germline GATA2 mutations In adolescents with MDS and -7, 72% have germline GATA2 mutations GATA2 deficiency likely the most common underlying genetic defect predisposing to pediatric MDS.

28 Key features Typical onset in early adulthood, variable presentation Cytopenias of monocytes, B cells, and NK cells, Unusual infection: disseminated non-tuberculous mycobacterial (NTM) and other opportunistic infections (HPV) A high risk of developing MDS and AML Poor survival once MDS/AML arises Allogeneic stem cell transplantation (allo-sct)

29 Diagnostic Clues Peripheral blood Dendritic cell, NK, B-Cell cytopenia Monocytopenia Neutropenia Bone marrow Hypocellular for age Megakaryocytic atypia/dysplasia Flow cytometry: absence or very few monocytes, B-cell precursors, B-cells, dendritic cells, NK-cells; inverted CD4:CD8 ratios

30

31 Types of inherited cytopenia Type Genetics Mechanism Fanconi anemia AR DNA repair Dykeratosis congenita XL, AD, AR Telomere maintenance Shhwachman-Diamond syndrome Diamond-Blackfan anemia Congenital dyserythropietic anemia AR AD, or XL in GATA1 related AR (I and II, AD (IIIand IV) Risosomal assembly Risosomal biogenesis Unfolded protein response TF Severe congenital neutropenia ELANE mutation Familial platelet disorder with myeloid malignancy RUNX1 AD AD Unfolded protein response HSC diff GATA2 deficiency AD HSC diff

32 Take home message GATA2 deficiency has a broad spectrum of phenotype including MonoMAC, MDS/AML, pulmonary disease and vascular/lymphatic dysfunction Diagnostic clues include cytopenia (monopenia, lack of HG), hypocellular marrow and dysmegs Early screening and family counseling are essential SCT is curative

33 Synopsis of cytopenias in PID. Conceptual overview, excluding primary defects of phagocyte number or function, inherited non-pid bone marrow failure syndromes, and disorders of isolated lymphopenia (without other cytopenia). *Includes hypomorphic mutations... Markus G. Seidel Blood 2014;124:

34 Clinical presentation: Warts, fungal infections, lymphedema, pulmonary alveolar proteinosis, aplastic anemia, MDS and AML Clinical features suggestive of GATA2 deficiency: persistent warts, lymphedema, pulmonary alveolar proteinosis or disseminated, and/or unusual infections.

35 GATA2 is expressed in hematopoietic progenitors and in nonhematopoietic embryonic stem cells (MIM: ) Heterozygous pathogenic variants in the GATA2 gene complex congenital immunodeficiency, which predisposes to infection and myeloid malignancy (Spinner et al., 2014). This includes autosomal dominant monocytopenia and mycobacterial infection (MonoMAC) syndrome, NK-cell deficiency, and primary lymphedema with myelodysplasia, also known as Emberger syndrome (Hsu et al., 2011; Hsu et al., 2013; Ostergaard et al., 2011; Seo et al., 2016). Additional features of Emberger syndrome can include sensorineural deafness, generalized warts, and facial dysmorphism (Mansour et al., 2010). Multiple variant types deep intronic variants from a highly conserved region within intron 4 (Stenson et al., 2014; Hsu et al., 2013; Wlodarski et al., 2016).

36 Annals of Hematology (2018) 97:

37 GATA2 p.r396w: p.arg396trp (CGG>TGG): c.1186 C>T in exon 6 in the GATA2 gene (NM_ ). The R396W variant in the GATA2 gene has been reported previously in two individuals with monocytopenia and mycobacterial infection (MonoMAC) syndrome (Hsu et al., 2011; Camargo et al., 2013). In addition, a different missense substitution at this position (R396Q) has been reported in association with MonoMAC syndrome (Hsu et al., 2011). The R396W variant is not observed in large population cohorts (Lek et al., 2016). The R396W variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. In-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. We interpret R396W as a likely pathogenic

38 Diagnostic Clues Radiologic Crazy paving on chest CT Subpleural blebs Paraseptal emphysema Ground glass opacities Splenomegaly

39 GATA2 deficiency GATA2 encodes a zinc finger TF necessary for normal hematopoiesis located on chromosome 3q21.2. Heterozygous germline mutations in GATA2 leading haploinsufficiency DCML deficiency (dendritic cell, moncytes, B, and NK deficiency) MonoMAC Familial MDS/AML Emberger syndrome (MDS with lymphedema). Autosomal-dominant disorders

40

41 a family with three affected individuals in two generations with severe congenital deafness in addition to lower limb lymphedema of childhood onset and hematological abnormalities (two with pancytopenia and one with AML). One member of the same family had isolated deafness and another had isolated lymphedema of the left lower limb (onset at 26 years). The latter, a female first cousin, once removed, at the age of 48 developed cirrhosis of the liver, mitral valve sclerosis, and cerebellar atrophy. Autosomal dominant inheritance with variable penetrance was suggested.

42

43

Case Presentation. Pei Lin, M. D.

Case Presentation. Pei Lin, M. D. Case Presentation Pei Lin, M. D. History A 26 yr man reports a history of numerous skin and upper respiratory infections as a child, including lymphadenitis and meningitis. In March 2013 during a preoperative

More information

Mild Megakaryocyte Atypia in a Patient with Presumed Germline GATA2 Mutation, and Active Mycobacterial Infection.

Mild Megakaryocyte Atypia in a Patient with Presumed Germline GATA2 Mutation, and Active Mycobacterial Infection. CASE TYPE: GERMLINE MUTATIONS OR FAMILIAL SYNDROMES PREDISPOSING TO MYELOID OR LYMPHOID NEOPLASMS. Mild Megakaryocyte Atypia in a Patient with Presumed Germline GATA2 Mutation, and Active Mycobacterial

More information

Meanings of the Word Gata

Meanings of the Word Gata Meanings of the Word Gata English Armenian Pastry Catalan female cat Fijian snake Hiligaynon coconut milk Icelandic street (noun), to pierce (verb) Norwegian gate Portuguese female cat, very beautiful

More information

Acute Myeloid Leukemia with RUNX1 and Several Co-mutations

Acute Myeloid Leukemia with RUNX1 and Several Co-mutations Case SH2017-0281 Acute Myeloid Leukemia with RUNX1 and Several Co-mutations James Bauer, MD, PhD David Yang, MD Erik Ranheim, MD, PhD Catherine Leith, MB, Bchir Clinical History Chief Complaint: 72 year

More information

UKGTN Testing Criteria

UKGTN Testing Criteria UKGTN Testing Criteria Test name: Inherited Bone Marrow Failure Syndromes 44 Gene Panel Approved name disorder/(s): See Appendix 1 Approved name (s): See Appendix 1 (s): (s): Patient name: Patient postcode:

More information

CHALLENGING CASES PRESENTATION

CHALLENGING CASES PRESENTATION CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Submitting laboratory: Bristol RGC 1. Disorder/condition approved name and symbol as published on the OMIM database (alternative

More information

7/13/2017. PreventionGenetics. How are genes associated with bone marrow failure?

7/13/2017. PreventionGenetics. How are genes associated with bone marrow failure? Personalized Medicine: tic Testing and the Implications for Future Therapies Preventiontics Michael Chicka, PhD, Molecular ticist, Preventiontics Founded in 2004 in Marshfield Wisconsin by Dr. Jim Weber

More information

Chronic Myelomonocytic Leukemia with molecular abnormalities SH

Chronic Myelomonocytic Leukemia with molecular abnormalities SH Chronic Myelomonocytic Leukemia with molecular abnormalities SH2017-0351 Madhu P. Menon MD,PhD, Juan Gomez MD, Kedar V. Inamdar MD,PhD and Kristin Karner MD Madhu P Menon, MD, PhD Henry Ford Hospital Patient

More information

SESSION 1 Reactive cytopenia and dysplasia

SESSION 1 Reactive cytopenia and dysplasia SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships

More information

Myelodysplastic syndromes

Myelodysplastic syndromes Myelodysplastic syndromes Robert P Hasserjian Massachusetts General Hospital, Boston, MA Disclosure of Relevant Financial Relationships Dr. Hasserjian declares he has no conflict(s) of interest to disclose.

More information

Myelodysplastic Syndrome Case 158

Myelodysplastic Syndrome Case 158 Myelodysplastic Syndrome Case 158 Dong Chen MD PhD Division of Hematopathology Mayo Clinic Clinical History 86 year old man Persistent borderline anemia and thrombocytopenia. His past medical history was

More information

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative

More information

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD

Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2

More information

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Case Workshop of Society for Hematopathology and European Association for Haematopathology Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history

More information

Genetic Predisposition Syndromes in Myeloid Malignancies

Genetic Predisposition Syndromes in Myeloid Malignancies Genetic Predisposition Syndromes in Myeloid Malignancies Lucy A. Godley, M.D., Ph.D. Section of Hematology/Oncology Departments of Medicine and Human Genetics The University of Chicago My patients and

More information

The function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018

The function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018 The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry

More information

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017 Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis

More information

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed Case #1 65 yo man with no prior history presented with leukocytosis and circulating blasts: WBC 187.4K/uL ; Hgb 10.0gm/dL; Platelet 68K/uL Neutrophil % 25.0% Lymphocyte % 38.0% Monocyte % 12.0% Metamyelocyte

More information

MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?

MDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do? 101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone

More information

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,

More information

When Cancer Looks Like Something Else: How Does Mutational Profiling Inform the Diagnosis of Myelodysplasia?

When Cancer Looks Like Something Else: How Does Mutational Profiling Inform the Diagnosis of Myelodysplasia? Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

CASE 106. Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation

CASE 106. Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation CASE 106 Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation Gabriel C. Caponetti, MD University of Pennsylvania, US Clinical history 69, F peripheral neuropathy, refractory

More information

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM

Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew

More information

Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options

Outline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases

More information

Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency

Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency REGULAR ARTICLE Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency Kevin E. Fisher, 1,2 Amy P. Hsu, 3 Christopher L. Williams, 2 Hadi

More information

Session II: Summary. Robert P Hasserjian, MD Professor of Pathology Massachusetts General Hospital and Harvard Medical School

Session II: Summary. Robert P Hasserjian, MD Professor of Pathology Massachusetts General Hospital and Harvard Medical School Session II: Summary Robert P Hasserjian, MD Professor of Pathology Massachusetts General Hospital and Harvard Medical School Disclosure of speaker s interests (Prefix and Last Name) (Potential) conflict

More information

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Myeloproliferative Disorders - D Savage - 9 Jan 2002 Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2

More information

Aplastic Anemia: Understanding your Disease and Treatment Options

Aplastic Anemia: Understanding your Disease and Treatment Options Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant

More information

Extramedullary precursor T-lymphoblastic transformation of CML at presentation

Extramedullary precursor T-lymphoblastic transformation of CML at presentation Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency

More information

Let s Look at Our Blood

Let s Look at Our Blood Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood

More information

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic

More information

2007 Workshop of SH/EAHP. Session 5 Therapy-related myeloid neoplasms

2007 Workshop of SH/EAHP. Session 5 Therapy-related myeloid neoplasms 2007 Workshop of SH/EAHP Session 5 Therapy-related myeloid neoplasms Classification: Key issues MDS vs. AML-M6 MDS vs. MDS/MPD Genetically defined entities Relevance of morphologic classification Clinical

More information

Can somatic GATA2 mutation mimic germ line GATA2 mutation?

Can somatic GATA2 mutation mimic germ line GATA2 mutation? EXCEPTIONAL CASE REPORT Can somatic mutation mimic germ line mutation? Mallika Sekhar, 1,2 Rachael Pocock, 3 David Lowe, 4 Christopher Mitchell, 3 Teresa Marafioti, 5 Rachel Dickinson, 6 Matthew Collin,

More information

Hematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD

Hematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,

More information

Laboratory Service Report

Laboratory Service Report Client C7028846-DLP Rochester Rochester, N 55901 Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-zwselwql7p.ashx Indication for Test DS CR Pathogenic

More information

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section: Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:

More information

2013 AAIM Pathology Workshop

2013 AAIM Pathology Workshop 2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone

More information

APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE

APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE APPROACH TO MYELODYSPLASTIC SYNDROMES IN THE ERA OF PRECISION MEDICINE Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics Department of Hematopathology The University

More information

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,

More information

Table 1: biological tests in SMD

Table 1: biological tests in SMD Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional

More information

Next Generation Sequencing Panel for Familial Myelodysplastic Syndrome/Acute Leukemia (MDS/AL)

Next Generation Sequencing Panel for Familial Myelodysplastic Syndrome/Acute Leukemia (MDS/AL) Next Generation Sequencing Panel for Familial Myelodysplastic Syndrome/Acute Leukemia (MDS/AL) Clinical Features and Molecular Genetics: The familial occurrence of myelodysplastic syndrome (MDS) and/or

More information

ACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016

ACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016 Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose

More information

Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome

Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Molecular profiling of early MDS Hematopathology - March 2016 Article Molecular profiling in confirming the diagnosis of early myelodysplastic syndrome Maya Thangavelu 1,*, Ryan Olson 2, Li Li 2, Wanlong

More information

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment

More information

A pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH

A pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH A pediatric patient with acute leukemia of ambiguous lineage with a NUP98NSD1 rearrangement SH20170203 Rebecca LeemanNeill, Ronald Rice, Anita Malek, Patricia Raciti, Susan Hsiao, Mahesh Mansukhani, Bachir

More information

Acute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg

Acute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:

More information

Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia

Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng

More information

DISCLOSURE Luca Malcovati, MD. No financial relationships to disclose

DISCLOSURE Luca Malcovati, MD. No financial relationships to disclose ICUS, CCUS and CHIP Luca Malcovati, MD Department of Molecular Medicine, University of Pavia Medical School, & Department of Hematology Oncology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy DISCLOSURE

More information

Adult Acute leukemia. Matthew Seftel. August

Adult Acute leukemia. Matthew Seftel. August Adult Acute leukemia Matthew Seftel August 21 2007 mseftel@cancercare.mb.ca Principles 3 cases Diagnosis and classification of acute leukemia (AL) Therapy Emergencies Remission induction BMT Complications

More information

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic

More information

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH ) Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and

More information

3/31/2014. New Directions in Aplastic Anemia Treatment: What s on the Horizon? Objectives

3/31/2014. New Directions in Aplastic Anemia Treatment: What s on the Horizon? Objectives New Directions in Aplastic Anemia Treatment: What s on the Horizon? AA & MDS International Foundation Living with, MDS, or PNH Patient and Family Conferences in 2014 April 5, 2014 Objectives To provide

More information

A Practical Approach to Leukopenia/Neutropenia in Children. Vandy Black, M.D., M.Sc., FAAP OLOL Children s Hospital August 24, 2014

A Practical Approach to Leukopenia/Neutropenia in Children. Vandy Black, M.D., M.Sc., FAAP OLOL Children s Hospital August 24, 2014 A Practical Approach to Leukopenia/Neutropenia in Children Vandy Black, M.D., M.Sc., FAAP OLOL Children s Hospital August 24, 2014 Disclosures EPIC trial MAST Therapeutics SUSTAIN trial Selexys Pharmaceuticals

More information

Leukocytopenias. -lymphocytopenia. -neutropenia. -monocytopenia. BHS seminar 8Nov2014

Leukocytopenias. -lymphocytopenia. -neutropenia. -monocytopenia. BHS seminar 8Nov2014 Leukocytopenias -lymphocytopenia -monocytopenia -neutropenia BHS seminar 8Nov2014 2010 Universitair Ziekenhuis Gent Prof.dr.Lucien Noens, Hematology and Bloodbank, Ghent University hospital Neutrophil

More information

Recommended Timing for Transplant Consultation

Recommended Timing for Transplant Consultation REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org

More information

5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA

5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana

More information

MYELODYSPLASTIC SYNDROMES

MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias

More information

Cancer Epidemiology. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD

Cancer Epidemiology. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Cancer Epidemiology Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Fanconi Anemia Adults, February 2011 Outline Epidemiology FA Literature

More information

Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes

Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes Hematopoietic Cell Transplantation in Bone Marrow Failure Syndromes The The 44 th th WBMT WBMT SYMPOSIUM 2017 2017 Riyadh, Saudi Saudi Arabia Arabia Mouhab Mouhab Ayas, Ayas, MD MD Department of Pediatric

More information

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07

More information

Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression

Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.

More information

Aplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood

Aplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood

More information

Correspondence should be addressed to Anas Khanfar;

Correspondence should be addressed to Anas Khanfar; Case Reports in Oncological Medicine, Article ID 949515, 4 pages http://dx.doi.org/10.1155/2014/949515 Case Report Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion

More information

Ordering Physician CLIENT,CLIENT. Collected REVISED REPORT

Ordering Physician CLIENT,CLIENT. Collected REVISED REPORT HPWET Hematopathology Consultation, MML Embed Client Hematopathology Consult REVISED INAL DIAGNOSIS Interpretation Peripheral blood, bone marrow aspirate and biopsies, bilateral iliac crests: 1. Normocellular

More information

Precursor T acute lymphoblastic leukemia from myelodysplastic syndrome in Fanconi anemia

Precursor T acute lymphoblastic leukemia from myelodysplastic syndrome in Fanconi anemia J Hematopathol (2013) 6:161 165 DOI 10.1007/s12308-012-0168-2 CASE REPORT Precursor T acute lymphoblastic leukemia from myelodysplastic syndrome in Fanconi anemia Julie C. Dueber & Claudio Mosse & Catherine

More information

Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions

Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions Myelodysplastic syndromes: revised WHO classification and distinction from non-neoplastic conditions Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical School

More information

MDS: Who gets it and how is it diagnosed?

MDS: Who gets it and how is it diagnosed? MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian

More information

Therapy-related acute myeloid leukemia with germline TP53 mutation (Li-Fraumeni syndrome) SH Chelsey Deel MD Teresa Scordino MD

Therapy-related acute myeloid leukemia with germline TP53 mutation (Li-Fraumeni syndrome) SH Chelsey Deel MD Teresa Scordino MD Therapy-related acute myeloid leukemia with germline TP53 mutation (Li-Fraumeni syndrome) SH2017-167 Chelsey Deel MD Teresa Scordino MD Clinical History HPI: 44 year old Caucasian female referred for evaluation

More information

Approaching Neutropenia in Children. SW Florida Osteopathic Medical Society: 39 th Annual Seminars in Family Practice

Approaching Neutropenia in Children. SW Florida Osteopathic Medical Society: 39 th Annual Seminars in Family Practice Approaching Neutropenia in Children SW Florida Osteopathic Medical Society: 39 th Annual Seminars in Family Practice Approaching Neutropenia in Children Emad Salman M.D Golisano Children s Hospital of

More information

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral

More information

Blood 101 Introduction Blood and Marrow & Overview of Bone Marrow Failure Diseases. Dr. M. Sabloff October 16 th 2010

Blood 101 Introduction Blood and Marrow & Overview of Bone Marrow Failure Diseases. Dr. M. Sabloff October 16 th 2010 Blood 101 Introduction Blood and Marrow & Overview of Bone Marrow Failure Diseases Dr. M. Sabloff October 16 th 2010 Normal Marrow knee joint white is articular cartilage Adjacent to this is the red marrow

More information

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014 Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Birmingham RGC Approved: September 2012

More information

Laboratory Service Report

Laboratory Service Report Specimen Type Peripheral blood CR PDF Report available at: https://test.mmlaccess.com/reports/c7028846-ih2xuglwpq.ashx Indication for Test DS CR Pathogenic utations Detected CR 1. JAK2: c.1849g>t;p.val617phe

More information

A Familial Bleeding Disorder: Revised Diagnosis after 30 Years

A Familial Bleeding Disorder: Revised Diagnosis after 30 Years A Familial Bleeding Disorder: Revised Diagnosis after 30 Years Abdullah Kutlar MD-Medical College of Georgia, Augusta, GA Allison Spellman MD-Summit Cancer Care, Savannah, GA Case Presentation 44y/o WF

More information

Etiology. Definition MYELODYSPLASTIC SYNDROMES. De novo. Secondary MDS (10 years earlier than primary) transformation

Etiology. Definition MYELODYSPLASTIC SYNDROMES. De novo. Secondary MDS (10 years earlier than primary) transformation MYELODYSPLASTIC SYNDROMES Rashmi Kanagal-Shamanna, MD Assistant Professor Hematopathology & Molecular Diagnostics The University of Texas M.D. Anderson Cancer Center Houston, Texas No relevant COIs to

More information

RUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016

RUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016 www.lls.org www.runx1.com RUNX1 and FPD/AML Translational Research The Leukemia and Lymphoma Society / Babich Family Foundation Partnership September 2016 Prepared by L. Greenberger, PhD Chief Scientific

More information

2011: ALL Pre-HCT. Subsequent Transplant

2011: ALL Pre-HCT. Subsequent Transplant 2011: ALL Pre-HCT The Acute Lymphoblastic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific pre-hct data such as: the recipient s hematologic and cytogenetic

More information

Management of Myelodysplastic Syndromes

Management of Myelodysplastic Syndromes Management of Myelodysplastic Syndromes Peter L. Greenberg, MD Stanford Cancer Institute Myelodysplastic Syndromes: Clinical & Molecular Advances for Disease Classification and Prognostication MDSs: A

More information

HEMATOLOGIC MALIGNANCIES BIOLOGY

HEMATOLOGIC MALIGNANCIES BIOLOGY HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION

More information

What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification

What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic

More information

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure I am receiving an honorarium from Sysmex for today s presentation. 1 Determining the Etiology for

More information

Year 2002 Paper two: Questions supplied by Jo 1

Year 2002 Paper two: Questions supplied by Jo 1 Year 2002 Paper two: Questions supplied by Jo 1 Question 70 A 25 year old previously well male student presents with recent exertional dyspnoea, epistaxis and bruising. There is no history of medication,

More information

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME

More information

Platelet and WBC disorders

Platelet and WBC disorders Division of Family Practice Platelet and WBC disorders Adrian Yee MD FRCPC Clinical hematologist Assistant Dean, undergraduate education, IMP asyee@uvic.ca When we understand that slide, we'll have won

More information

Heme 9 Myeloid neoplasms

Heme 9 Myeloid neoplasms Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the author to give readers additional information about his work. Supplement to: Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved

More information

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16 35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will

More information

BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016

BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016 BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016 David Rice, PhD, RN, NP Director, Professional Practice

More information

Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328

Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Kenneth N. Holder, Leslie J. Greebon, Gopalrao Velagaleti, Hongxin Fan, Russell A. Higgins Initial Case: Clinical

More information

Aplastic Anemia Pathophysiology and Approach to Therapy

Aplastic Anemia Pathophysiology and Approach to Therapy Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes

More information

Clonal hematopoiesis of indeterminate potential and MDS. Siddhartha Jaiswal AAMDS Meeting 3/17/16

Clonal hematopoiesis of indeterminate potential and MDS. Siddhartha Jaiswal AAMDS Meeting 3/17/16 Clonal hematopoiesis of indeterminate potential and MDS Siddhartha Jaiswal AAMDS Meeting 3/17/16 Clonal evolution from birth to death Might pre-malignant clones, bearing only the initiating lesion, be

More information

Myeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:

Myeloid neoplasms. Early arrest in the blast cell or immature cell we call it acute leukemia Myoid neoplasm divided in to 3 major categories: Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid

More information

Spectrum of somatically acquired mutations identified by combining WES and genome-wide DNA array analysis in the discovery cohort of 30 JMML cases.

Spectrum of somatically acquired mutations identified by combining WES and genome-wide DNA array analysis in the discovery cohort of 30 JMML cases. Supplementary Figure 1 Spectrum of somatically acquired mutations identified by combining WES and genome-wide DNA array analysis in the discovery cohort of 30 JMML cases. A total of 85 somatically acquired

More information

Myelodysplastic Syndromes Myeloproliferative Disorders

Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation

More information

Update on Clinically Relevant Genetic Alterations in AML and Recommendations for Molecular Testing

Update on Clinically Relevant Genetic Alterations in AML and Recommendations for Molecular Testing Update on Clinically Relevant Genetic Alterations in AML and Recommendations for Molecular Testing Amir Behdad, M.D. LoAnn C. Peterson, M.D. Feinberg Medical School, Northwestern University Chicago, Illinois

More information

Myelodysplastic syndromes and the new WHO 2016 classification

Myelodysplastic syndromes and the new WHO 2016 classification Myelodysplastic syndromes and the new WHO 2016 classification 32nd General Annual Meeting of the Belgian Hematology Society 10-11 February 2017 Gregor Verhoef, Departement of Hematology, University Hospital

More information

CLINICAL USE OF CELLULAR SUBPOPULATION ANALYSIS IN BM

CLINICAL USE OF CELLULAR SUBPOPULATION ANALYSIS IN BM CLINICAL USE OF CELLULAR SUBPOPULATION ANALYSIS IN BM CANCER RESEARCH CENTRE, UNIVERSITY AND UNIVERSITY HOSPITAL OF SALAMANCA (SPAIN)( Sao Paulo, 18th of April, 2009 IDENTIFICATION OF HPC (I) 1.- In vivo

More information

Case Workshop of Society for Hematopathology and European Association for Haematopathology

Case Workshop of Society for Hematopathology and European Association for Haematopathology Case 24 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Aliyah Rahemtullah 1, Martin K Selig 1, Paola Dal Cin 2 and Robert P Hasserjian 1 Departments of Pathology,

More information